Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.
Phase 1 other active
Quick answer
Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions. for not applicable (submitted trial is bioavailability) is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- not applicable (submitted trial is bioavailability)
- Phase
- Phase 1
- Modality
- other
- Status
- active